Swift Weight Rebound and Erosion of Health Advantages Upon Discontinuing GLP-1s

Individuals revert to their original weight and forfeit every cardiometabolic advantage within fewer than two years after discontinuing semaglutide or tirzepatide, as uncovered by a recent meta-analysis.

Real-world data suggests that roughly half of individuals with obesity cease use of GLP-1 receptor agonists within one year of starting, making it crucial to understand body weight changes post-treatment cessation, noted Sam West, a postdoctoral researcher in the Nuffield Department of Primary Care Health Sciences at the University of Oxford in England, along with his team in their publication dated January 7, 2026, in The BMJ.

The findings, derived from 9341 individuals across 37 investigations covering various weight-reduction drugs including older options, indicated a return to initial weight on average after 1.7 years. The typical monthly weight regain stood at 0.4 kg, roughly four times quicker than following behavioral approaches, irrespective of the original weight shed. Projected cardiometabolic improvements were expected to revert to baseline levels even faster upon halting GLP-1s.

These medications prove highly potent and serve as a key resource in addressing obesity, yet obesity represents a recurring chronic issue. It's evident that ongoing management or therapeutic measures must persist to uphold the advantages of such therapies, remarked co-author Susan Jebb, PhD, OBE, a professor of Diet and Population Health at the same Oxford institution, in a briefing organized by the Science Media Centre.

Jebb elaborated that these pharmaceuticals should be viewed as a single choice among broader obesity management strategies. They do not constitute the sole approach to obesity care. To optimize value for the UK's National Health Service (NHS), selecting the appropriate intervention for the suitable individual at the ideal moment is vital, given the vast population that stands to gain.

In a related editorial, Qi Sun, MD, an associate professor of medicine at Brigham and Women's Hospital and Harvard Medical School in Boston, stated that GLP-1 receptor agonists cannot be depended upon as a miraculous solution for obesity. Although notable, even temporary weight reduction can offer certain health perks for those with obesity, users of these drugs ought to recognize the elevated discontinuation likelihood and the fallout from medication cessation. Sound eating habits and lifestyle choices must form the cornerstone of obesity prevention and control, with pharmaceuticals like GLP-1s acting as supplementary aids. These habits not only avert unwarranted weight accumulation but also deliver extensive health advantages extending past mere weight management.

The research highlights that weight regain intensifies upon drug discontinuation, observed Adam Collins, PhD, from the University of Surrey in England, noting that preserving weight loss poses a significant hurdle.

Artificially elevating GLP-1 levels might lead to diminished natural production in patients. This poses no issue during medication use, but upon withdrawal of this GLP-1 boost, appetite remains unchecked, raising the odds of excessive eating. Similar to an individual overcoming addiction abruptly, this transition proves daunting. The difficulty heightens if the person depended exclusively on GLP-1 for appetite suppression without adopting lasting dietary or behavioral modifications to sustain long-term progress, Collins further explained.

What Occurs Upon Ceasing Weight-Reduction Drugs?

In the examined studies, all treatments lasted at least 8 weeks, with monitoring spanning a minimum of 4 weeks, involving adults who were overweight or obese. The group included 6322 treatment participants and 3019 controls. Treatment typically extended 10 months, followed by 8 months of observation.

Participants shed an average of 8.3 kg during therapy but recovered 4.8 kg within one year, at a monthly pace of 0.4 kg. They reached their starting weight around 1.7 years after ending treatment.

In a focused review of 1776 individuals from six trials on semaglutide and tirzepatide, the mean weight reduction was 14.7 kg, followed by a recovery of 9.9 kg at 0.8 kg per month, with an anticipated baseline return in 1.5 years. (Projections were used since data for these drugs extended only to one year.)

Every cardiometabolic marker evaluated, such as A1c, blood sugar levels after fasting, systolic and diastolic blood pressure, overall cholesterol, and triglycerides, was also forecasted to revert to initial levels within 1.4 years post-cessation.

For context, an earlier investigation by the same researchers on weight recovery following non-drug weight-loss initiatives revealed smaller reductions of 5.1 kg, but slower regain at 0.1 kg monthly, with a longer path back to baseline of 3.9 years. Larger initial losses often lead to quicker regain, yet it remains consistently faster with medications, regardless of starting weight loss, West pointed out in his briefing presentation.

Adding behavioral assistance during incretin mimetic therapy boosted weight loss by an additional 4.6 kg. Nevertheless, no proof existed that behavioral support altered the regain speed, either during or following treatment, as West detailed.

Are These Drugs Economically Viable for the NHS?

The UK's National Institute for Health and Care Excellence deems an intervention financially worthwhile at £20,000 to £30,000 per extra quality-adjusted life-year (QALY). Therefore, it views incretins as cost-effective for select groups: individuals with BMI of 35 or higher and a related condition, assuming regain at one year for tirzepatide (£21,372), and those with BMI between 30-35 plus risks or 35+ for semaglutide (£21,060), projecting regain at two years.

Yet, these latest results imply potentially swifter regain, potentially shifting the cost-benefit analysis, commented co-author Dimitrios A. Koutoukidis, PhD, from Oxford.

He mentioned that the NHS is presently implementing based on medical necessity, focusing on higher BMI or more complications, which could enhance affordability. Alternative weight-loss methods might prove more economical, such as behavioral dietary plans for non-eligible individuals under NHS guidelines (~£2394/QALY) or gastric bypass for severe/complex obesity (~£7129/QALY).

Jebb emphasized that with these being novel medications, extended post-treatment observations in trials are sparse. As adoption grows, examining emerging real-world evidence becomes essential to assess prolonged outcomes. This represents an initial glimpse, she concluded.

The initiative received partial backing from the National Institute of Health and Care Research (NIHR) Oxford Biomedical Research Centre. Jebb acknowledged support from the NIHR Oxford Biomedical Research Centre, NIHR Oxford Health Biomedical Research Centre, and NIHR Oxford and Thames Valley Applied Research Collaboration. Koutoukidis noted receipt of an NIHR advanced fellowship. Jebb and West disclosed partial funding from a Novo Nordisk Foundation research grant. Collins reported no conflicts.

Health tracking apps like Shotlee can assist in monitoring weight changes after stopping these medications.